Resources
Explore the 4eva Pep Product Library
Find product identities, label-derived formulation information, and supporting documentation in one clear resource.
Product library
The 4eva Pep Collection
Understanding Product Information
Each product page is organized around the product name, listed ingredients, listed amount or strength, and available package details. Storage or handling information appears only when it has been supplied for that product. This library provides product navigation and factual label information; it does not provide dosing, administration, or treatment guidance.
Product Documentation
Where product-specific documentation is available and approved for customer access, it appears with the applicable product rather than in an unrelated generic library. Supporting material may include certificates, test documentation, or batch and lot records. A product page remains free of document claims when no approved public document is associated with it.
Reading Research Context
A studied mechanism is not the same as an established product outcome. Preclinical literature describes CJC-1295 as a long-acting GHRH analog and ipamorelin as a growth-hormone secretagogue acting through a GHRP-like receptor pathway. Those findings do not establish that their combination improves body composition, recovery, or another commonly marketed outcome in people.
Retatrutide remains investigational. The FDA states that it is not a component of an approved drug and has not been found safe and effective for any condition. The 4eva Pep development listing does not represent FDA approval, a treatment indication, or human-use guidance.
FDA: concerns with unapproved GLP-1 drugs · CJC-1295 preclinical record · Ipamorelin preclinical pharmacology